Open and endoscopic carpal-tunnel releases are commonly used as the definitive treatment for carpal tunnel syndrome. This ...

Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate ...

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.

An urgent health care workforce crisis is looming. In the United States, a country plagued by disparate health outcomes across its geographic regions, relative physician “deserts” (i.e ...

A quantitative alcohol history should be recorded for all patients, because alcohol use contributes to many physical and mental disorders. A person-centered, nonjudgmental approach should be adopted.

Zoledronate prevents fractures when given every 12 to 18 months, but its effects on bone health persist well beyond 5 years. New research findings on very infrequent zoledronate dosing in early ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue ...

Dr. Kalen N. Wright (Emergency Medicine): A 21-year-old man with sickle cell disease was evaluated in the emergency department of this hospital after loss of consciousness resulting in a fall.

In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.

Patients with residual invasive HER2-positive early breast cancer after neoadjuvant systemic therapy have a poor prognosis. Adjuvant therapy with trastuzumab emtansine has shown improved outcomes.